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Application of mathematical algorithms to sequenced whole genomes revealed a large number of predicted genes, requiring functional assays
for their characterization in a high-throughput manner. Here, we report on the development of a screening assay, which is based on reverse
transfection of cellular arrays and subsequent analysis of cell morphology to identify novel proapoptotic genes. Expression plasmids containing
full-length cDNAs were cotransfected with the reporter plasmid pEYFP to screen for apoptotic body formation, based on EYFP fluorescence. The
assay was validated and applied to 382 human sequence-verified full-length open reading frames, most of them of unknown function. In this initial
screening, proapoptotic effects could be demonstrated for 10 of these genes. For 6 of them apoptosis induction could be confirmed both by
TUNEL assay and by FACS analysis of cells stained according to Nicoletti: 1 gene was not yet annotated for an apoptotic function (ST6GAL2),
while 5 genes were without annotated function (FLJ20551, CXorf12, FAM105A, TMEM66, C19orf4). Our study demonstrates the potential of this
method to characterize functionally genes of unknown function in a highly parallel format.
© 2006 Elsevier Inc. All rights reserved.Keywords: Reverse transfection; Cell array technology; Apoptosis; Caspase; Nuclear morphologyAnalysis of sequenced genomes disclosed a plethora of genes
of unknown function, providing opportunities for genome-wide
functional characterizations [1]. Methods used to characterize
genes of unknown function include (i) algorithms searching for
homologies between protein subdomains [2,3], (ii) overexpres-
sion of the gene of question, and (iii) knockout or knockdown of
individual genes [4]. A promising technology developed for the
characterization of unknown genes in a highly parallel format is
the reverse transfection of arrayed cDNAs [5]. In comparison to
conventional transfection, components are applied in a parallel
format in a different order. First, the expression plasmid, contain-
ing the cDNA to be analyzed, is complexed with transfection
reagent. The complex is subsequently spotted on a glass slide,Abbreviations: ORF, open reading frame; EYFP, enhanced yellow
fluorescent protein; GDM, gelatin–DNA method; LDM, lipid–DNA method;
FACS, fluorescence-activated cell sorting; RZPD, Resource Center Primary
Database; DAPI, 4′,6-diamidino-2-phenylindole; HEK, human embryonal
kidney; TUNEL, terminal deoxynucleotidyl transferase biotin–dUTP nick-end
labeling; GOA, Gene Ontology Annotation.
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doi:10.1016/j.ygeno.2005.12.009which is overlaid in the next step with a suspension of adherently
growing cells. Seeded cells will adhere to the surface, become
transfected, and express the respective proteins. Following the first
publication of the reverse transfection assay, the technique was
applied for the development of a variety of screening assays [6–9].
To screen for apoptosis-related genes, the original protocol
was adopted and modified to meet the special requirements for
screening for proapoptotic genes. Assays measuring caspase
activity using fluorogenic substrates or phosphatidylserine ex-
position by annexin V staining are limited to the detection of
specific pathways only. To overcome this handicap, we assessed
a late event of apoptosis, the apoptotic body formation. Themain
advantage of the reverse transfection technology is its potential
to screen large numbers of genes for a particular function. In
addition, the method allows for the assessment of not only the
apoptotic phenotype but also other phenotypic changes.
Furthermore, cell-based assays employing immunohistochem-
istry or detection of protein interaction can be easily adapted.
We proved the applicability of the assay by screening 382
randomly selected human sequence-verified, full-length ORFs
for novel proapoptotic genes.
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Optimization of reverse transfection
An optimized protocol for reverse transfection was devel-
oped, based on the lipid–DNA method (LDM) [5]. In addition
to the LDM, we also tested the gelatin–DNA method (GDM)
[5]. For the GDM, expression plasmids were mixed with a
gelatin solution and arrayed onto poly-L-lysine-coated slides.
The arrays were subsequently incubated with the transfection
reagent. For transfection via the LDM, expression plasmids
were premixed with the transfection reagent and the gelatin
solution and printed onto the slides. After either of the two
methods, the arrays were overlaid with a suspension of
adherently growing cells. Two days after transfection, the
cells were fixed and analyzed.
We tested both methods for suitability for reverse
transfection, using the pEYFP plasmid as a reporter for
transfection efficiency. The LDM yielded consistently good
expression results over the whole spotted surface. In our
hands, using the GDM, often large areas were not transfected
and many spots did not show detectable EYFP fluorescence.
Due to the homogeneous transfection of the array obtained
with the LDM, we decided to use it as the basis for our
screening assay.
Regarding the LDM, the concentrations of sucrose and gela-
tin in the transfection mixture play an important role in both
transfection efficiency and spot integrity. Low sucrose concen-
tration is insufficient to maintain the DNA–transfection reagent
complex stable, whereas high sucrose concentration disturbs
immobilization, as transfected cells are spread outside the spots
(Fig. 1A). Low gelatin concentration reduces transfection effi-
ciency (Fig. 1A). For all further experiments, we used 34 mM
sucrose and 0.2% gelatin.
The transfection efficiency for HEK293T cells obtained by
the optimized LDM was around 50%. To yield statistically
reliable results and allow for the identification of genes with low
efficacy in inducing apoptosis, a sufficiently high number of
cells was needed. Therefore, we employed spotting pins with a
delivery volume of 12.5 nl to obtain a mean spot diameter of
600 μm, which resulted in 100–400 transfected cells growing
within these spots.
Detection of apoptosis after reverse transfection
Our goal was to test for a late apoptotic marker, covering
various apoptotic pathways. After reverse transfection, we
screened for three well-characterized events occurring at theFig. 1. Development of a screening assay for proapoptotic genes by reverse transfecti
and adhesion of expression plasmids. (B) Assessment of gene expression levels for d
plasmid were reversely transfected. The cells were fixed and the spots examined for
assay was performed to compare nuclear fragmentation, DNA cleavage, and appeara
image of a single spot. Bottom: Fluorescence images of the same section of a single
(C) As negative control, 0.6 μg reporter plasmid pEYFP was reversely transfecte
microarray scanner. Bar, 600 μm. Top right: Fluorescence image of a single spot. B
positive cells of a section of a spot. Bar, 50 μm. (D) As positive control, 0.6 μg repo
cotransfected. Images as in (C). (E) ST6GAL2- and EYFP-expressing cells exhibitend of the apoptotic cascade: apoptotic body formation, DNA
cleavage, and fragmentation of the nucleus. As a reference
gene for apoptosis induction, the proapoptotic Bax gene, which
encodes a murine mitochondrial membrane protein, was used.
To visualize apoptotic bodies, we cotransfected pEYFP as
reporter plasmid. DNA cleavage was detected using the
TUNEL assay on the cell array, which labels free 3′-OH
termini with modified nucleotides in an enzymatic reaction.
Fragmented nuclei were visualized by DAPI staining. Cells
expressing EYFP and mouse Bax were examined for
appearance of apoptotic bodies, DNA cleavage, and fragmen-
tation of the nuclei (Fig. 1B, middle and bottom). Apoptotic
bodies appeared as small intense green fluorescent blebs,
accumulating EYFP. There were many more fragmented nuclei
than nuclei containing cleaved DNA. Visual inspection of
numerous spots revealed in each case only very few TUNEL-
positive nuclei. One example is shown in Fig. 1B (see also
Discussion). In addition, there were more apoptotic bodies
visible than fragmented nuclei, since a single cell releases
several apoptotic bodies.
Determination of gene expression levels for detection of
apoptosis
The optimal range of Bax and reporter plasmid pEYFP ex-
pression had to be established to obtain optimal induction of
apoptosis along with sufficient visibility of the spots and apop-
totic bodies. We tested the range of Bax and pEYFP expression
using 0.2–0.8 μg transfected DNA (Fig. 1B, top). The optimal
ratio of Bax/pEYFP in the transfection mix was 1:1, using 0.6 μg
of each plasmid. This ratio was used in all further screening
experiments.
As a negative control, the reporter plasmid pEYFP was
selected. pEYFP (0.6 μg) was printed and reversely transfected.
Spots expressing the pEYFP plasmid alone yielded intense
fluorescence due to strong expression of the EYFP protein (Fig.
1C). As a positive control, 0.6 μg of the expression vector
containing Bax was transfected, along with 0.6 μg of pEYFP.
Cells exhibited formation of apoptotic bodies and fragmentation
of the nucleus (Fig. 1D).
Functional analysis of 382 genes of mostly unknown function
To screen for new proapoptotic proteins, 382 full-length
ORFs, 92% of which were genes without annotation for a
biological process, were randomly selected from Library 970
of the RZPD. We selected this library since it contains a large
number of genes with unknown function. Expression plasmidson. (A) Influence of sucrose and gelatin concentration on transfection efficiency
etection of apoptosis. Different amounts of EYFP and a murine Bax-expressing
appearance of apoptotic bodies. Nuclei were stained with DAPI and the TUNEL
nce of apoptotic bodies. Top: Fluorescence scan of EYFP. Middle: Fluorescence
spot. Arrows show fragmented nuclei. (C, D) Validation of the control plasmids.
d alone. Top left: Fluorescence scan of EYFP-expressing cell clusters with a
ottom left and right: Fluorescence images of DAPI-stained nuclei and EYFP-
rter plasmid pEYFP and 0.6 μg expression vector containing the Bax gene were
apoptotic bodies (arrows) and fragmented nuclei (DAPI).
667O. Mannherz et al. / Genomics 87 (2006) 665–672were cospotted in four replicates with the reporter pEYFP and
transfected into HEK293T cells using the LDM. After fixation,
the appearance of apoptotic bodies was assessed by visual
inspection. As an example, ST6GAL2 is shown in Fig. 1E.
Phenotypic changes were scored only when present on at leasttwo of the four replicate spots and on at least two of three
analyzed slides. Ninety-three percent of the 382 screened
ORFs displayed a normal phenotype (Table 1). Ten genes
were identified, the transfection of which resulted in the
appearance of apoptotic bodies. Only 1 of these, ANT1, was
Table 1
Distribution of the observed morphological changes
Screened genes in total 382 100%
Genes causing phenotypic changes 26 6.8%
Proapoptotic genes a 7 1.8%
Genes causing rounded phenotype a 21 5.5%
Genes causing dented nuclei a 8 2.1%
Other morphology a 9 2.4%
No phenotypic changes observed 356 93.2%
a Overlap of phenotypes, see Table 2.
668 O. Mannherz et al. / Genomics 87 (2006) 665–672previously known to induce apoptosis [10]. The remaining 9
genes were retested for DNA cleavage by TUNEL staining
without pEYFP. In addition to apoptotic body formation, DNA
fragmentation was observed for 6 of the genes; 4 of them are
shown in Fig. 2. For 1 of these, an apoptotic function had not
been assigned yet (ST6GAL2), while 5 of the proapoptotic genes
had no previously annotated function (genes FLJ20551,
CXorf12, FAM105A, TMEM66, C19orf4). In addition to the 7
genes inducing apoptosis, 19 genes caused distinct morpholog-Fig. 2. Validation of the identified genes using TUNEL staining. Empty vector, Bax, a
Nuclei were stained by DAPI, apoptotic nuclei were stained using the TUNEL assaical changes: rounded cells, dented nuclei, small round
condensed nuclei, large nucleoli, condensed chromosome
clusters, protruding cellular processes, or abnormally shaped
cells (see Table 2 and Supplementary Fig. S1). Notably,
overexpression of several genes causing distinct phenotypes
also led to a roundish cell shape, indicating a decreased
adherence to the glass slide surface (see Table 2 and
Supplementary Fig. S1).
Quantitation of induction of apoptosis by the identified genes
To assess the potential for induction of apoptosis, the six
validated proapoptotic genes, as well as Bax and the empty
vector as controls, were transfected into HEK293T cells. These
were subsequently subjected to Nicoletti staining after an
incubation of 48 h. In this assay, the cytoplasm is removed
and fragmented DNA diffuses out of the nucleus. Apoptotic
nuclei can be detected based on reduced DNA content compared
to the normal G1 population. After transfection, apoptotic nuclei
could be measured with fluorescence-activated cell sortingnd four of the identified proapoptotic genes were transfected into HEK293Tcells.
y.
Table 2






Apoptosis Rounded cells Dented nuclei Other morphology
Solute carrier family 25, member 4 SLC25A4 BC008664 + +
Hypothetical protein FLJ20551 FLJ20551 BC013194 +
ST6 beta-galactosamide alpha-2,6-sialytranferase 2 ST6GAL2 BC008680 + +
Chromosome X open reading frame 12 CXorf12 BC008203 + + +
Family with sequence similarity 105, member A FAM105A BC011524 + +
Chromosome 19 open reading frame 4 C19orf4 BC010446 + +
Transmembrane protein 66 TMEM66 BC015012 + +
Chromosome 19 open reading frame 32 C19orf32 BC008201 + + Small round condensed nuclei
Transmembrane protein 109 TMEM109 BC001309 + Small round condensed nuclei
Chromosome 12 open reading frame 23 C12orf23 BC020522 + Small round condensed nuclei
Chromosome 20 open reading frame 195 C20orf195 BC000912 +
SFT2 domain containing 3 SFT2D3 BC006808 +
Adiponectin receptor 1 ADIPOR1 BC010743 +
Chromosome 14 open reading frame 169 C14orf169 BC011350 + Large nucleoli
Solute carrier family 41, member 3 SLC41A3 BC009039 + +
Ring finger protein 121 RNF121 BC009672 + +
Chromosome 22 open reading frame 5 C22orf5 BC015489 + +
Transmembrane BAX inhibitor motif containing 1 TMBIM1 BC013428 + +
Transmembrane protein 112 TMEM112 BC010738 + +
Leucine-rich repeat neuronal 6A LRRN6A BC011057 + +
Dehydrogenase/reductase (SDR family) member 7B DHRS7B BC009679 +
Chromosome 1 open reading frame 96 C1orf96 BC015419 + Condensed chromosomes
Chromosome 16 open reading frame 56 C16orf56 BC015202 Condensed chromosomes
Protein phosphatase 1A (formerly 2C),
magnesium-dependent, alpha isoform
PPM1A BC026691 Condensed chromosomes
Transmembrane protein 24 TMEM24 BC022219 Neuron-like cells
Tubulin-specific chaperone cofactor e TBCE BC008654 Abnormally shaped cells
669O. Mannherz et al. / Genomics 87 (2006) 665–672(FACS) (Fig. 3A). Two of the proapoptotic genes induced
apoptosis in 30–40% of the cells (FLJ20551, ST6GAL2), two in
20–25% of the cells (CXorf12, FAM105A), and two in 7%
(C19orf4, TMEM66) (Fig. 3B). To investigate the involvement
of caspases in apoptosis execution of these genes, the pan-
caspase inhibitor Z-VAD-fmk was added to each transfection
setup in a parallel experiment. Apoptosis induction could be
reduced to 2.5–5% by the presence of Z-VAD-fmk for the genes
FLJ20551, ST6GAL2, CXorf12, C19orf4, and TMEM66. In
contrast, around 10% of Bax- or FAM105A-transfected cells
were driven into apoptosis.
Discussion
Optimization of reverse transfection for screening for
proapoptotic genes
The reverse transfection technology allows highly parallel
functional characterization of genes. It has been applied in
various screening settings, including (i) a high-throughput phe-
notype screening microscopy platform [8], (ii) a setup for the
screening of phenotypes caused by gene silencing [9], (iii) high-
throughput selection of effective RNAi probes [6], and (iv)
monitoring of mitogen-activated protein kinase signaling [7].
However, none of these methods has been validated in follow-up
screening studies. In this work, we demonstrate that our ap-
proach based on the reverse transfection method is a powerful
tool to screen for proapoptotic genes. We opted for the reversetransfection because it offers the possibility of assessing mor-
phological changes, such as apoptotic body formation, at a high
resolution. As imaging platforms for acquisition of high-
resolution images of large areas become more sophisticated,
application of pattern recognition software could be implemen-
ted for automated detection of apoptotic bodies.
We preferred to use the lipid–DNA transfection method,
which resulted in homogeneous transfection of a given cell array.
Using the GDM, the critical step was to remove the Hybri-Well
chamber after incubation of the spotted array with the trans-
fection reagent. Thereby, the chamber came into contact with
parts of the arrayed surface, resulting in low transfection effi-
ciency for large areas of the array.
For detection of apoptosis nuclear fragmentation, DNA clea-
vage and appearance of apoptotic bodies were compared.
TUNEL staining labeled only a few of the fragmented nuclei
(Fig. 1B). The TUNEL assay seems specific for a very late phase
of apoptosis, which is not reached yet in the remaining frag-
mented nuclei. The difference between the numbers of nuclei
fragmented and the TUNEL-positive nuclei (which are only a
small subset of the same nuclei) is explained well by the fact that
fragmentation of the DNA, detected by the TUNEL assay, takes
place at a time point later than fragmentation of the nucleus [11].
Intensity and number of TUNEL-positive nuclei were not suffi-
cient to identify apoptotic spots. In contrast, screening for
apoptotic bodies showed reliable results, since apoptotic cells
fragment into many apoptotic bodies. The optimal ratio of the
concentration of pEYFP to the concentration of the expression
Fig. 3. Quantification of apoptotic cell populations after overexpression of the identified genes by FACS. Empty vector, Bax, and the identified proapoptotic genes
were transfected into HEK293T cells. Harvested cells were incubated with Nicoletti buffer. Apoptotic nuclei appearing in the sub-G1 phase were quantified. (A)
Histograms showing apoptotic, G1, and G2 cell populations. (B) Apoptotic cell populations were quantified from two transfection experiments, in the presence or
absence of the pan-caspase inhibitor Z-VAD-fmk. Nuclei were stained using the Nicoletti buffer to quantify apoptotic cells by FACS. Error bars represent the standard
deviation of two independent experiments.
670 O. Mannherz et al. / Genomics 87 (2006) 665–672clones was 1:1, using 0.6 μg of each plasmid (Fig. 1B). When
replica spots of four are used for each cDNA, up to 200 different
ORFs can be screened on one poly-L-lysine coated slide.
Identification of proapoptotic genes by reverse transfection of
an expression library
Traditional approaches to screen for proapoptotic genes target
different downstream caspases. However, detection of single
caspases depicts only a subset of proapoptotic molecules. As
apoptotic bodies represent an endpoint of virtually all apoptotic
pathways, they are superior as phenotypic markers of apoptosis
for a screening approach. Furthermore, the assay is highly spe-cific, since the appearance of apoptotic bodies is exclusively
assigned to apoptotic processes. High sensitivity of the assay
could be confirmed by the quantification of apoptotic cell popu-
lations by FACS analysis: two apoptotic genes were identified
by reverse transfection that induced apoptosis in only 7% of the
cells as measured by FACS (C19orf4, TMEM66) (Fig. 3B).
THREE hundred eighty-two genes were screened, 352 of
which had no annotation to a biological process if strong
evidence codes (other than inferred from electronic annotation,
or IEA) were considered, according to the Gene Ontology
Annotation (GOA) database [12]. The assay was validated by
the detection of a previously known apoptosis-inducing gene,
the solute carrier family 25, member 4 (SLC25A4). SLC25A4 is a
671O. Mannherz et al. / Genomics 87 (2006) 665–672mitochondrial membrane protein known to trigger apoptosis by
overexpression [10]. Other than the SLC25A4 gene, 9 further
genes previously not known for their apoptotic potential were
identified and 6 of these 9 were confirmed for their proapoptotic
function by TUNEL assay, Nicoletti assay, and caspase
inhibition. Thus, 1.8% of the screened genes induced apoptosis.
Considering only strong evidence codes, the GOA database lists
18,628 gene products without annotation to a biological process
[12]. Extrapolating our finding of 1.8% apoptotic genes, one
could expect to identify some 330 novel proapoptotic genes by
this assay, keeping in mind that extrapolation is based on small
numbers. The GOA database lists 8381 genes with an annotation
(non-IEA) to a biological process, 234 (2.8%) of them are
proapoptotic. According to these numbers, our assay might
allow for the identification of 65% of all possible proapoptotic
genes.
Expression status of these genes was examined in silico in
different cancer entities using the cancer microarray database
Oncomine [13]. With the exception of FLJ20551, five of the
identified proapoptotic genes were downregulated in one or
more different cancer entities (Table S1) [14–19]. Thus, the
functional assay presented here also allows one to pinpoint
individual candidate genes with oncogenic potential.
In summary, this screening approach demonstrates that the
assay is a powerful technique for the functional characterization
of genes. Our method could substantially contribute to the
elucidation of the function for those more than 18,000 genes for
which no function has been assigned yet.
Materials and methods
Expression library
Three hundred eighty-two randomly selected human sequence-verified full-
length ORFs (for a list of all genes see Table S2) from Library 970 were obtained
from the RZPD. This library is a compilation of human sequence-verified full-
length ORFs selected from libraries of the NIHMammalian Gene Collection and
the IMAGEConsortium. It contains clones of the Escherichia coli strain DH10B
transformed with cDNAs unidirectionally inserted into the pCMV-Sport6
expression vector. Plasmids were isolated using the QIAprep Spin Miniprep Kit
(Qiagen, Hilden, Germany).
Cell culture, reverse transfection, cell fixation
Human HEK293T (human embryonal kidney) cells (ATCC CRL-1573)
were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum, 100
U/ml penicillin, and 100 μg/ml streptomycin at 37°C and 5% (v/v) CO2. Reverse
transfection was based on the protocol published by Ziauddin et al. [5]. For the
GDM, 0.6 μg pEYFP (BD Biosciences Clontech, Palo Alto, CA, USA) plasmid
and 0.6 μg expression plasmid were added to 13 μl of 0.2% (w/v) gelatin
solution (G-9391; Sigma–Aldrich, Munich, Germany), ensuring that the gelatin
concentration was above 0.17%. The DNA–gelatin solution was arrayed in
quadruplicate onto poly-L-lysine-coated Poly-Prep Slides (Sigma–Aldrich)
using the Omnigrid (GeneMachines, San Carlos, CA, USA) microarrayer and
SMP15B spotting pins (TeleChem International, Sunnyvale, CA, USA). Dot
spacing was 1000 μm, mean spot diameter was 600 μm for all experiments.
Slides were stored at room temperature in a dry atmosphere until further
processing, for up to 4 weeks. Subsequently, the incubation chamber Hybri-Well
(Sigma–Aldrich) with adhesive edges was attached to the spotted area and the
array was incubated with the transfection reagent Effectene (Effectene
Transfection Kit; Qiagen). The transfection reagent mix was prepared as
follows: 150 μl EC buffer was mixed with 16 μl Enhancer and incubated for 5min at room temperature. Twenty-five microliters of Effectene was subsequently
added and the solution was distributed into the Hybri-Well and incubated for 20
min at room temperature. After the transfection reagent and the incubation
chamber were removed the slide was ready for transfection.
For the LDM 0.6 μg pEYFP plasmid, 0.6 μg expression plasmid, and 1.5 μl
Enhancer were successively added to 15 μl EC buffer containing 0.1 M sucrose.
The mixture was incubated for 5 min at room temperature. Subsequently, 5 μl
Effectene was added and again incubated for 10 min at room temperature. A 1×
volume of 0.4% (w/v) gelatin (G-9391; Sigma–Aldrich) was mixed with the
solution to complete the transfection master mix. Arrayed slides were stored as
described above.
Slides were placed in QuadriPERM plates (Vivascience, Hannover,
Germany), overlaid with 2.2 × 106 HEK293T cells, and cultured for 48 h in
DMEM supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin,
and 100 μg/ml streptomycin. Cells were fixed for 60 min at room temperature in
3.7% (w/v) paraformaldehyde (Merck, Darmstadt, Germany) in phosphate-
buffered saline. Fixed cells were permeabilized (0.1% sodium citrate (w/v),
0.1% (v/v) Triton X-100 (Sigma–Aldrich) in phosphate-buffered saline) for 5
min, washed two times for 5 min in phosphate-buffered saline, overlaid with
Vectashield mounting medium containing DAPI (Vector Laboratories, Burlin-
game, CA, USA), and covered with a coverslip (24 × 40 mm; R. Langenbrinck,
Teningen, Germany). Slides were scanned with a GenePix 4000A microarray
scanner (Axon Instruments, Union City, CA, USA) to evaluate transfection
efficiency and EYFP expression. Morphologic and nuclear changes were
assessed using the epifluorescence microscope Axioplan (Zeiss, Jena,
Germany). Fluorescence images were acquired on the epifluorescence
microscope Axioplan (Zeiss) by using the CCD camera ORCA-ER-1394
(Hamamatsu Photonics K.K., Hamamatsu City, Japan).
Standard transfection
HEK293T cells (2 × 105) in 2000 μl DMEM supplemented with 10% (v/v)
fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin were
seeded into six-well plates 12 h before transfection. For the TUNEL assay
circular 12-mm diameter coverslips were placed into the plate before seeding.
Plasmid DNA (0.5 μg) was added to 500 μl EC buffer followed by 3.2 μl
Enhancer (Effectene kit; Qiagen), mixed, and incubated at room temperature.
After 5 min, 10 μl Effectene was added. The mixture was incubated at room
temperature for 10 min. Finally, 500 μl fresh medium was added to the ready
transfection mixture. This was carefully pipetted onto the cells, and the plate was
placed in an incubator at 37°C and 5% (v/v) CO2 for 48 h. The pan-caspase
inhibitor Z-VAD-fmk (Alexis Biochemicals, Grünberg, Germany) was used at
20 μM concentration and administered every 12 h due to its instability. Cells
were harvested for the Nicoletti assay [20] or fixed for TUNEL assay on the
coverslips as described above.
Apoptosis assays
For imaging of apoptotic nuclei, TUNEL assays were performed using the In
Situ Cell Death Detection Kit, TMR red (Roche Diagnostics, Mannheim,
Germany), according to the manufacturer’s instructions.
To measure the extent of apoptosis induction by the identified proapoptotic
genes, Nicoletti assays were performed. Cells from a six-well microtiter plate
were harvested and washed 1× with phosphate-buffered saline. One-tenth of the
amount of harvested cells was suspended in 80 μl Nicoletti buffer (0.1% (w/v)
sodium citrate, pH 7.4, 0.1% (v/v) Triton X-100, 50 μg/ml propidium iodide)
and incubated at 4°C in the dark. The DNA content present in the resulting
nuclei was determined by FACS using a BD FACSArray Bioanalyzer System
(BD Biosciences, San Jose, CA, USA). Sub-G1 cells were considered apoptotic.
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